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Introduction
Methotrexate (MTX) is the cornerstone disease-modifying
anti-rheumatic drug in juvenile idiopathic arthritis (JIA).
In JIA, it is important to start effective treatment early in
the course of disease, the so-called window of opportunity,
to avoid long term sequelae, such as joint damage. To
accomplish this goal, it is essential to know beforehand
who is going to respond well to MTX, so MTX mono-
therapy can be started in patients predicted to respond
well, whereas other drugs, such as biologicals, could be
prescribed to patients predicted to be non-responders.
In addition, MTX adverse effects, such as MTX intoler-
ance, occur frequently and can lead to non-compliance,
thus hindering its efficacy. Therefore, to avoid inefficacy of
an otherwise efficacious drug, the physician should timely
be aware of these adverse events.
Objectives
The aim of this study was to identify predictors for
MTX efficacy and adverse events.
Methods
A systematic literature search was performed in PubMed,
Embase and The Cochrane Library, and 1,331 articles
were identified. These were selected based on their rele-
vance, and critically appraised according to pre-defined
criteria. Predictors for MTX efficacy and adverse events
were tabulated.
Results
Twenty articles were selected. For MTX efficacy, some
interesting candidate predictors were found, such as
antinuclear antibody positivity, the childhood health
assessment questionnaire score, the myeloid-related pro-
tein 8/14 level, long-chain MTX polyglutamates, bilateral
wrist involvement and some single nucleotide polymorph-
isms (SNPs) in the adenosine triphosphate binding cassette
and solute carrier transporter gene families. For MTX
adverse events, potential predictors were alanine amino-
transferase and thrombocyte level and two SNPs in the g-
glutamyl hydrolase and methylenetetrahydrofolate reduc-
tase genes. Validation of most predictors was still lacking.
Conclusion
Interesting candidate predictors were found, especially for
MTX efficacy. However, most of these have not yet been
validated in independent cohorts. The results of some can-
didate predictors were quite variable in different cohorts,
highlighting the difficulty to properly validate those, due
to heterogeneity between studies. A clinically relevant way
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